Company intelligence / Profile preview
HiberCell
New York City, New York, United Stateshibercell.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
HiberCell has initiated Phase I clinical trials for its lead candidate HC‑5404‑FU targeting PERK in advanced solid tumors. Another candidate, HC‑7366 targeting GCN2/EIF2AK4, was previously in clinical development but appears to be discontinued. The company’s approach centers on overcoming treatment resistance and preventing cancer relapse/metastasis by disrupting stress-adaptive pathways and tumor dormancy. Some pipeline assets have been discontinued or are at the preclinical stage. No late-stage or commercialized products as of May 2025.
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Small moleculesMonoclonal antibodiesChemical drugsPolymer-based therapeutics
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on HiberCell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HiberCell.